News and Announcements
FNN Interview with Managing Director of Tesserent
- Published March 07, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Tesserent Limited (ASX:TNT) is pleased to provide shareholders with an update on the company. During the interview with FNN, Keith Glennan discusses the following topics relating to Tesserent’s performance over the past 12 months and future growth opportunities.
KEY TAKEAWAYS:
- Tesserent’s proprietary security platform and why Tesserent is able to provide specialised security solutions for their customers.
- Tesserent’s response to market trends, including Tesserent’s approach to Secure Integrated Cloud Services.
- Recent amendment to the Privacy Act, introducing Data Breach Notification legislation and how Tesserent is experiencing immediate increased demand for security and reporting services as Australian businesses seek to meet their obligations under this new legislation.
- Update on the sale of MyNet IP to Family Zone (ASX:FZO) for $3.5m in cash and 1m FZO shares. Tesserent has received $1.5m cash from Family Zone, with a further $2m cash due from Family Zone on 31st May 2017. Ahead of this payment, Family Zone has confirmed today they have raised $2.85m cash (ASX Announcement)
Tesserent is a specialist in managed cyber security. Tesserent has built its own platform for the delivery of managed cyber-security, which it deploys for the management of its own customers and also licenses to partners around the world to enable them to deliver effective cyber-security management to their customers.
To view the video of the FNN interview with Keith Glennan online, please use the link below.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
